NEW YORK (GenomeWeb) – Sophia Genetics and Genycell Biotech today announced a partnership to expand access to the Sophia Data Driven Medicine (Sophia DDM) platform. 

As part of the deal, Genycell will distribute Sophia DDM as part of a package to laboratories and hospitals in Spain and Portugal performing next-generation sequencing-based clinical diagnosis, a Sophia spokesman said. Sophia DDM uses machine learning and algorithms for genomic analysis of patient samples. 

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

This year's Breakthrough Prize winners include a pair that developed a therapy for spinal muscular atrophy.

The New York Times reports on how white supremacists misconstrue genetic research, concerning many geneticists.

Researchers find that people's genetics influence their success at university, but that it is not the only factor.

In Nature this week: approach to identify genetic variants that affect trait variability, application of read clouds to microbiome samples, and more.

Sponsored by
Sophia Genetics

With the Next Generation Sequencing (NGS), genomes sequencing has been democratized over the last decades with the detection of genomic alterations, thus replacing Sanger sequencing.